Biogen Idex (BIIB) CEO Scangos Says New MS Treatment Will Bolster Offerings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen Idec (BIIB) Sinks 8% After ALS Drug Fails, Development Stopped
January 3, 2013 7:37 AM ESTBiogen Idec (NASDAQ: BIIB) is trading down 8 percent after reporting top-line results of EMPOWER, a Phase 3 trial investigating... More
Biogen Idec (BIIB) Said FDA Extends PDUFA Date for BG-12 3 Months
October 18, 2012 8:08 AM EDTBiogen Idec (NASDAQ: BIIB) said the FDA has extended the initial... More
